ASHDOD, Israel, Jan. 12, 2016 /PRNewswire/ -- Integrity
Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a
non-invasive device for measuring glucose levels of people with
Type 2 diabetes and pre-diabetics, announced that it has hired
Eran Cohen as its Chief Operating
Officer (COO).
Mr. Cohen brings over 17 years of extensive and diversified
experience in global executive roles in high growth companies in
Israel and abroad. His previous
positions include Vice President of Operations, Vice President
of Global Services and Vice President of Finance and Operations
with leading NASDAQ high-tech and medical companies. Most recently
he was Vice President of Global Services for Lumenis Ltd., the
world leader in the design, manufacture, marketing and servicing of
laser and light based systems for aesthetic, ophthalmic, surgical
and dental applications. Prior to Lumenis Eran served as VP
operations at Cadent that was acquired by Align Technologies
(NASDAQ: ALGN). He has an Executive MBA from Tel-Aviv University, Recanati School of Management
and BSc. in Economics and Management from the Technion, Israel
Institute of Technology.
"We are very pleased to announce and welcome Eran as our Chief
Operating Officer," said Avner Gal,
Integrity Applications President and CEO. "His operational
experience, coupled with his hands on approach, will greatly
benefit us as we bring the upgraded GlucoTrack device to market in
2016. His position, as well as the International Sales and Business
Development Manager position that we announced last month reflects
our intent and preparation to aggressively execute the
commercialization of our product."
About GlucoTrack®
GlucoTrack® is a non-invasive device for measuring glucose
levels of people with Type 2 diabetes or at risk of developing
diabetes that does not require pricking of the fingers to draw
blood for daily glucose monitoring. GlucoTrack® features a small
sensor that clips to the earlobe and measures the wearer's glucose
level by taking measurements using three technologies. The measured
signals are analyzed using a proprietary algorithm and displayed on
a small handheld device, the size of a mobile phone. The derived
glucose measurement is also announced verbally, facilitating use by
elderly and vision-impaired diabetes patients.
The GlucoTrack® Model DF-F is expected to begin clinical
trials for United States FDA approval in early 2016, subject to
approval of Integrity Applications' clinical trials protocol by the
FDA.
GlucoTrack® Model DF-F obtained a CE Mark approval
in Europe (June 2013) and
final CE Mark approval in March 2014 and recently received
approval to market the device also to pre-diabetics.
GlucoTrack® Model DF-F is currently under assessment with the
China Food and Drug Administration (CFDA) as well as food and drug
governing bodies in Japan, South
Korea Canada and Australia.
About Integrity Applications, Inc.
Integrity Applications, Inc. is a medical device company focused
on the design, development and commercialization of non-invasive
glucose monitoring devices for use by people with diabetes.
Integrity Applications has developed the GlucoTrack® model DF-F
non-invasive glucose monitoring device, which is designed to help
people with diabetes obtain glucose level measurements without the
pain, inconvenience, incremental cost and difficulty or discomfort
of conventional (invasive) spot finger stick devices. Integrity
Applications operates primarily through its wholly-owned Israeli
subsidiary, A.D. Integrity Applications, Ltd. For more information,
please visit www.integrity-app.com.
Forward-Looking Statements
This news release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Statements contained in
this news release that are not statements of historical fact may be
deemed to be forward-looking statements. Without limiting the
generality of the foregoing, words such as "expect" and "will" are
intended to identify forward-looking statements. Readers are
cautioned that certain important factors may affect Integrity
Applications' actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect Integrity Applications'
results include, but are not limited to, the ability of Integrity
Applications to raise additional capital to finance its operations
(whether through public or private equity offerings, debt
financings, strategic collaborations or otherwise); risks relating
to the receipt (and timing) of regulatory approvals (including FDA
approval); risks relating to obtaining regulatory approval in
the United States and in foreign
jurisdictions; risks relating to the conduct of clinical trials;
risks relating to its current and future distribution agreements;
risks relating to its ability to hire and retain qualified
personnel, including sales and distribution personnel; and the
additional risk factors described in Integrity Applications'
filings with the U.S. Securities and Exchange Commission, including
its Annual Report on Form 10-K for the year ended December 31,
2015.
Contact:
Eran Hertz,
CFO Integrity Applications, +972 (8) 675-7878 Ext. 400,
eranh@integrity-app.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/glucotrack-maker-hires-chief-operating-officer-300202931.html
SOURCE Integrity Applications, Inc.